RECLAST Drug Patent Profile

Which patents cover Reclast, and when can generic versions of Reclast launch?

Reclast is a drug marketed by Sandoz and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-six patent family members in twenty-two countries.

The generic ingredient in RECLAST is zoledronic acid. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zoledronic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Reclast

A generic version of RECLAST was approved as zoledronic acid by DR REDDYS LABS LTD on March 4^th, 2013.

Summary for RECLAST

International Patents:	26
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	27
Patent Applications:	4,729
Drug Prices:	Drug price information for RECLAST
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RECLAST
What excipients (inactive ingredients) are in RECLAST?	RECLAST excipients list
DailyMed Link:	RECLAST at DailyMed

See drug prices for RECLAST

Recent Clinical Trials for RECLAST

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Australian and New Zealand Intensive Care Research Centre	Phase 2
University of Nebraska	Phase 1/Phase 2
San Francisco VA Health Care System	Phase 4

See all RECLAST clinical trials

Pharmacology for RECLAST

Drug Class

Bisphosphonate

Paragraph IV (Patent) Challenges for RECLAST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RECLAST	Injection	zoledronic acid	0.05 mg/mL, 100 mL vial	021817	1	2008-08-29

US Patents and Regulatory Information for RECLAST

RECLAST is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	RECLAST	zoledronic acid	INJECTABLE;INTRAVENOUS	021817-001	Apr 16, 2007	AP	RX	Yes	Yes					Y

Expired US Patents for RECLAST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	RECLAST	zoledronic acid	INJECTABLE;INTRAVENOUS	021817-001	Apr 16, 2007
Sandoz	RECLAST	zoledronic acid	INJECTABLE;INTRAVENOUS	021817-001	Apr 16, 2007

EU/EMA Drug Approvals for RECLAST

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Zoledronic Acid Accord	zoledronic acid	EMEA/H/C/002667Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2014-01-16
Actavis Group PTC ehf	Zoledronic acid Actavis	zoledronic acid	EMEA/H/C/002488Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-04-20
Mylan Pharmaceuticals Limited	Zoledronic acid Mylan	zoledronic acid	EMEA/H/C/002482Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2012-08-23
Pfizer Europe MA EEIG	Zoledronic Acid Hospira	zoledronic acid	EMEA/H/C/0023654 mg / 5 ml and 4 mg / 100 ml:Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).5 mg / 100 ml:Treatment of osteoporosis:in post-menopausal women;in men;at increased risk of fracture, including those with a recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:in post-menopausal women;in men;at increased risk of fracture.Treatment of Paget's disease of the bone in adults.	Authorised	yes	no	no	2012-11-19
Teva B.V.	Zoledronic acid Teva	zoledronic acid	EMEA/H/C/002439Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-08-16

International Patents for RECLAST

See the table below for patents covering RECLAST around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	045670	PRODUCTOS FARMACEUTICOS QUE COMPRENDEN BISFOSFONATOS
Hungary	199150	PROCESS FOR PRODUCING SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS ACTIVE INGREDIENT
Hungary	228400	THE USE OF BISPHOSPHONATES FOR TREATMENT OF OSTEOPOROSIS
Japan	4802096
Spain	2394211

Supplementary Protection Certificates for RECLAST

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1591122	C300582	Netherlands		PRODUCT NAME: ZOLEDRONZUUR, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, DAN WEL IEDER HYDRAAT DAARVAN; REGISTRATION NO/DATE: C(2007)4619 20071003
0258618	SPC/GB01/042	United Kingdom		PRODUCT NAME: ZOLEDRONIC ACID 2-(IMIDAZOL-1-YL)-1-HYDROXYETHANE-1,1-DIPHOSPHONIC ACID; REGISTERED: CH 55463 20001128; UK EU/1/01/176/001 20010320; UK EU/1/01/176/002 20010320; UK EU/1/01/176/003 20010320
1591122	2013C/022	Belgium		PRODUCT NAME: ACIDE ZOLEDRONIQUE; AUTHORISATION NUMBER AND DATE: C(2007)4619 20071003
1591122	92174	Luxembourg		PRODUCT NAME: ACIDE ZOLEDRONIQUE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE OU TOUT HYDRATE DE CELUI-CI
1591122	C01591122/01	Switzerland		PRODUCT NAME: ZOLEDRONSAEURE; REGISTRATION NO/DATE: SWISSMEDIC 57363 27.09.2007

RECLAST Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

RECLAST (zoledronic acid) is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone, and to prevent fractures in patients with bone metastases from solid tumors. Developed by Novartis, its market performance is influenced by patent exclusivity, generic competition, and therapeutic landscape evolution.

What is the Market Landscape for RECLAST?

The market for osteoporosis and bone metastasis treatments is competitive, featuring established therapies and newer entrants. RECLAST's position is characterized by its efficacy and established safety profile, but also by increasing generic penetration and evolving treatment guidelines.

Key Market Players and Competitive Therapies

Novartis' RECLAST has historically been a significant player. However, the market includes other bisphosphonates, as well as newer classes of drugs.

• Bisphosphonates:
  • Alendronate (Fosamax)
  • Risedronate (Actonel)
  • Ibandronate (Boniva)
  • Zoledronic acid (RECLAST, Zometa)
• Denosumab (Prolia): A monoclonal antibody that inhibits RANK ligand, offering a different mechanism of action and often perceived as having a more convenient dosing schedule (subcutaneous injection every six months).
• Anabolic Agents:
  • Teriparatide (Forteo)
  • Abaloparatide (Tymlos)
  • Romosozumab (Evenity) - A sclerostin inhibitor with dual action of bone formation and resorption inhibition.

The competitive intensity is driven by factors such as efficacy, safety profile, route of administration, dosing frequency, and cost.

Patent Exclusivity and Generic Entry

RECLAST's primary patent expired in the United States in 2018. This patent expiration has led to the introduction of generic versions of zoledronic acid, significantly impacting the brand's market share and pricing.

• US Patent Expiration: Primarily expired in 2018.
• European Patent Expirations: Varied by country, with many key markets seeing expirations in the early to mid-2010s.
• Generic Launches: Following patent expiry, multiple generic manufacturers entered the market with lower-cost alternatives.

The entry of generics has led to price erosion for zoledronic acid, forcing the brand RECLAST to compete more on established brand recognition and patient loyalty, alongside therapeutic advantages if any can be demonstrated.

What is RECLAST's Financial Trajectory?

The financial performance of RECLAST has transitioned from peak sales during its patent-protected period to a declining trajectory due to generic competition.

Historical Sales Performance

During its patent exclusivity, RECLAST achieved significant sales, driven by its approved indications for osteoporosis and bone metastases.

• Peak Sales: While specific annual figures fluctuate, RECLAST and its related intravenous formulation, Zometa, collectively generated billions in revenue for Novartis during their peak. For example, in 2015, Zometa and RECLAST combined sales were approximately $2.3 billion [1]. By 2020, combined sales had decreased to around $1.5 billion [1].
• Sales Decline Post-Generic Entry: Post-2018 in the US, the decline in RECLAST's sales accelerated as healthcare providers and payers shifted towards more cost-effective generic zoledronic acid and competing therapies.

The financial trajectory reflects a typical pattern for branded pharmaceuticals following patent expiry.

Current Market Value and Projections

Current market value for the RECLAST brand is significantly lower than its peak. Projections are generally for continued decline, with market share held by generics and newer therapeutic classes.

• Brand Sales in Recent Years:
  • 2021: Approximately $635 million globally [1].
  • 2022: Approximately $554 million globally [1].
  • 2023: Preliminary figures indicate further decline, with reported sales of $472 million in the first nine months of 2023 [1].

These figures illustrate a consistent downward trend, primarily attributable to generic competition and the ongoing evolution of osteoporosis and bone oncology treatment paradigms.

What are the Key Drivers of RECLAST's Performance?

Several factors influence RECLAST's market position and financial outcomes, encompassing clinical utility, regulatory aspects, and economic considerations.

Clinical Utility and Physician Adoption

RECLAST's established efficacy in reducing fracture risk is a primary driver. Its intravenous administration, while requiring clinical setting visits, can be advantageous for patients with gastrointestinal absorption issues or adherence challenges with oral bisphosphonates.

• Approved Indications:
  • Osteoporosis treatment and prevention.
  • Paget's disease of bone.
  • Prevention of skeletal-related events (fractures, spinal cord compression, need for radiation or surgery to bone) in patients with bone metastases from solid tumors (primarily breast cancer, multiple myeloma, and prostate cancer).
• Administration: Intravenous infusion, typically once yearly for osteoporosis and every 3-4 weeks for bone metastases, depending on the indication and product formulation.
• Efficacy: Clinical trials have demonstrated RECLAST's significant reduction in vertebral, hip, and non-vertebral fractures in postmenopausal women with osteoporosis [2]. It has also shown efficacy in reducing skeletal-related events in patients with bone metastases [3].

Physician confidence in its established efficacy and safety profile, albeit with known side effects like renal toxicity and osteonecrosis of the jaw, continues to support its use.

Reimbursement and Payer Policies

Reimbursement policies and payer coverage significantly impact drug utilization. As a branded drug facing generic competition, RECLAST's market access is heavily influenced by cost-effectiveness assessments.

• Formulary Placement: Insurers often place generic zoledronic acid on preferred tiers due to lower cost, limiting RECLAST's formulary advantages.
• Step-Therapy Protocols: Some payers may implement step-therapy protocols, requiring patients to try generic bisphosphonates or other treatments before approving RECLAST.
• Value-Based Pricing: Increasing emphasis on value-based pricing and comparative effectiveness research can influence payer decisions, potentially favoring newer agents with distinct benefits or generics for established therapies.

The cost differential between RECLAST and generic zoledronic acid is a primary driver of payer preference for generics.

Therapeutic Landscape Evolution

The development of new drug classes for osteoporosis and bone metastases, such as denosumab and anabolic agents, has diversified treatment options and altered the competitive landscape.

• Denosumab (Prolia/Xgeva): Offers a different mechanism of action and a more convenient subcutaneous injection schedule. Prolia is for osteoporosis, and Xgeva is for bone metastases.
• Anabolic Agents: Teriparatide, abaloparatide, and romosozumab offer bone-building capabilities, representing a significant advancement for patients with severe osteoporosis or those unresponsive to antiresorptive agents.
• Combination Therapies: Research into optimal sequencing and combination therapies continues to evolve, potentially favoring agents with distinct mechanisms.

These advancements introduce higher-cost, potentially more efficacious or convenient alternatives, drawing market share away from older therapies like RECLAST.

What are the Future Prospects for RECLAST?

The future of RECLAST is characterized by continued decline in brand sales, with its therapeutic role likely diminishing as generic zoledronic acid and newer agents capture market share.

Impact of Generic Competition

Generic zoledronic acid will continue to be the primary driver of pricing pressure and market share erosion for the RECLAST brand.

• Price Erosion: Ongoing price competition among multiple generic manufacturers will sustain lower average selling prices compared to the branded product.
• Market Share Shift: Healthcare providers and payers will continue to favor generic options for cost savings, limiting RECLAST's market penetration.

Role in Specific Patient Populations

RECLAST may retain a niche role in specific patient populations where its established brand recognition, or specific clinical considerations, outweigh the cost advantage of generics.

• Patients with Swallowing Difficulties: Intravenous administration remains an advantage for some.
• Specific Hospital Protocols: Some institutions may maintain the brand for historical or logistical reasons.
• Long-Term Indication Management: For patients on long-term therapy established before generic availability, physician inertia might preserve some brand use.

However, these niche applications are unlikely to offset the overall downward sales trend.

Novartis' Strategic Focus

Novartis' strategic focus is likely on its pipeline of newer therapeutic agents and mature brands with ongoing patent protection or market dominance. RECLAST's contribution to the company's portfolio is expected to decrease.

• Pipeline Prioritization: Resources are likely allocated to newer, higher-growth therapeutic areas and pipeline assets.
• Portfolio Optimization: Mature products facing significant generic competition are often de-prioritized in terms of marketing and sales investment.

The long-term strategic value of the RECLAST brand for Novartis is limited by its mature lifecycle stage and intense generic competition.

Key Takeaways

RECLAST's market trajectory is a case study in the impact of patent expiry and generic competition on branded pharmaceuticals. Its sales have declined significantly from peak levels, driven by the availability of lower-cost generic zoledronic acid. While RECLAST's established efficacy in osteoporosis and bone metastases supported substantial historical revenue, the competitive landscape has evolved with the introduction of newer therapeutic classes like denosumab and anabolic agents. These alternatives, offering different mechanisms of action, improved convenience, or enhanced efficacy, further erode RECLAST's market share. Reimbursement policies and payer preferences increasingly favor cost-effective generic options. Future prospects for the RECLAST brand involve continued sales decline, with its role potentially confined to niche patient populations. Novartis' strategic focus is likely to shift towards higher-growth assets, further diminishing the strategic importance of RECLAST within its portfolio.

Frequently Asked Questions

1. When did RECLAST's primary US patent expire? RECLAST's primary US patent expired in 2018.
2. What are the main therapeutic areas for which RECLAST is approved? RECLAST is approved for the treatment and prevention of osteoporosis, Paget's disease of bone, and the prevention of skeletal-related events in patients with bone metastases from solid tumors.
3. What is the primary reason for RECLAST's declining sales? The primary reason for RECLAST's declining sales is the entry of generic versions of zoledronic acid following patent expiry, leading to significant price erosion and market share loss.
4. How does denosumab (Prolia/Xgeva) compete with RECLAST? Denosumab competes by offering a different mechanism of action and a more convenient subcutaneous injection schedule, appealing to patients and physicians seeking alternatives to intravenous bisphosphonates.
5. What is the current global sales trend for RECLAST? RECLAST's global sales have shown a consistent downward trend in recent years, with figures decreasing from approximately $635 million in 2021 to $472 million in the first nine months of 2023.

Citations

[1] Novartis AG. (2021-2023). Novartis Annual Reports and Quarterly Results Presentations. (Specific report dates vary, but data is sourced from publicly available financial disclosures). [2] Mcclung, M. R., et al. (2009). Zoledronic acid versus alendronate in postmenopausal women with osteoporosis. New England Journal of Medicine, 360(18), 1819-1830. [3] Rosen, L. S., et al. (2003). A comparison of zoledronic acid and pamidronate for the treatment of bone metastases in patients with advanced multiple myeloma. Journal of Clinical Oncology, 21(16), 3038-3043.